Estudo randomizado | Vigilância ativa com enzalutamida em monoterapia vs. vigilância ativa isolada em pacientes com risco baixo ou intermediário de câncer de próstata localizado.

Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer – JAMA Oncology

Comentário convidado: To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence – JAMA Oncology (gratuito por tempo limitado)

Vídeo criticando o artigo: ENACT trial | A Study That Makes Pharma Rich and Patients’ Poor | I break it down – by Vinay Prasad

Comentários no Twitter

55% fatigue and 36% gynecomastia. In AS patients.

Why do we keep trying to escalate when the data CLEARLY say we should continue to de-escalate? https://t.co/LY1kD0jN65

— Chris Barbieri (@Chris_Barbieri1) June 17, 2022

The phase 2, open-label ENACT trial compares the efficacy & safety of enzalutamide monotherapy vs active surveillance in patients with low- or intermediate-risk localized #prostatecancer. https://t.co/q9FrL14em1 #PCSM #GUCSM

— JAMA Oncology (@JAMAOnc) June 16, 2022